Phase I/II study of albumin-bound nab-paclitaxel plus gemcitabine administered to Chinese patients with advanced pancreatic cancer
- 13 March 2013
- journal article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 71 (4) , 1065-1072
Abstract
The primary objective of this study was to evaluate the dose-limiting toxicities (DLTs) and identify the maximum-tolerated dose (MTD) and recommended dose of nab-paclitaxel plus gemcitabine as a first-line treatment in Chinese patients with advanced pancreatic ductal adenocarcinoma (PDA). Patients with previously untreated advanced PDA were treated with nab-paclitaxel followed by gemcitabine (1,000 mg/m2) administered intravenously for 30 min on days 1 and 8 and repeated every 21 days. Patients received nab-paclitaxel at the following dose levels: 80 mg/m2 (n = 3), 100 mg/m2 (n = 6), and 120 mg/m2 (n = 12). The DLTs evaluated were elevated alanine aminotransferase and febrile neutropenia. However, there had no two out of three to six patients experienced DLTs, the MTD was not met. A total of 93 cycles were administered. The most common grade 3/4 toxicities were neutropenia (9.52 %), thrombocytopenia (4.76 %), and sensory neuropathy (4.76 %). For 12 patients receiving 120 mg/m2, the overall response rate and disease control rate were 41.67 and 83.33 %, respectively, and the median progression-free survival and overall survival were 5.23 and 12.17 months, respectively. Treatment with albumin-bound nab-paclitaxel (120 mg/m2) plus gemcitabine has a favorable safety profile with an encouraging antitumor effect in Chinese patients.Keywords
This publication has 21 references indexed in Scilit:
- Are Risk Factors Associated with Outcomes in Pancreatic Cancer?PLOS ONE, 2012
- nab-Paclitaxel Potentiates Gemcitabine Activity by Reducing Cytidine Deaminase Levels in a Mouse Model of Pancreatic CancerCancer Discovery, 2012
- Gemcitabine Plusnab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II TrialJournal of Clinical Oncology, 2011
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerNew England Journal of Medicine, 2011
- Epidemiology of pancreatic cancer: an overviewNature Reviews Gastroenterology & Hepatology, 2009
- Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancerBMC Cancer, 2008
- Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane®) on three treatment schedules in patients with solid tumorsCancer Chemotherapy and Pharmacology, 2007
- Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel.Clinical Cancer Research, 2006
- Increased levels of SPARC (osteonectin) in human breast cancer tissues and its association with clinical outcomesProstaglandins, Leukotrienes and Essential Fatty Acids, 2005
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000